A5011305627- Testicular diseases and treatments
- Urologic and reproductive health conditions
- Sarcoma Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Neuroblastoma Research and Treatments
- Sexual Differentiation and Disorders
- Genital Health and Disease
- Prostate Cancer Diagnosis and Treatment
- Urological Disorders and Treatments
- Urinary and Genital Oncology Studies
- Cancer Immunotherapy and Biomarkers
- Sperm and Testicular Function
- Renal cell carcinoma treatment
- Cervical Cancer and HPV Research
- Multiple Myeloma Research and Treatments
- Prostate Cancer Treatment and Research
- Lymphatic System and Diseases
- Vascular Malformations and Hemangiomas
- Colorectal and Anal Carcinomas
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- Renal and Vascular Pathologies
- PARP inhibition in cancer therapy
- Urinary Bladder and Prostate Research
Saarland University
2016-2025
University of Oslo
2021-2024
Oslo University Hospital
2021-2024
Universitätsklinikum des Saarlandes
2014-2023
University Medical Center of Southern Nevada
2023
Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie
2020
Institute of Cell Biology
2018
Heidelberg University
2008-2016
University Hospital Heidelberg
2008-2016
University Medical Centre Mannheim
2008-2016
Previous studies suggested that serum levels of microRNA (miR)-371a-3p (so-called M371 test) have a much higher sensitivity and specificity than the classic markers testicular germ cell tumors (GCTs) are applicable toward both seminoma nonseminoma. We sought to confirm usefulness this test as novel biomarker for GCT.
Pembrolizumab and olaparib have shown single-agent activity in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC).To evaluate the efficacy safety of pembrolizumab plus mCRPC.Cohort A phase 1b/2 KEYNOTE-365 study enrolled molecularly unselected, docetaxel-pretreated mCRPC whose disease progressed within 6 mo screening.Pembrolizumab 200 mg intravenously every 3 wk 400-mg capsule or 300-mg tablet orally twice daily.The primary endpoints were safety,...
Abstract Purpose: Surveillance of clinical stage I (CSI) testicular germ cell tumors (GCT) is hampered by low sensitivity and specificity current biomarkers for detecting relapses. This study evaluated if serum levels microRNA371a-3p (M371 test) can: (i) Accurately detect relapses, (ii) relapses earlier than conventional technology, (iii) elevated postoperative M371 may predict relapse. Experimental Design: In a multicentric setting, 258 patients with CSI GCT were prospectively followed...
Clinical stage 1 (CS1) testicular seminoma involves an almost 100 % disease-specific survival in controlled clinical trials. We aimed to find out whether these results can be matched patients managed on the routine care level.In total, 725 with CS1 were prospectively enrolled from 130 institutions. Adjuvant management as decided by local physicians involved surveillance (n = 256), radiotherapy (41), 1× Carboplatin (362), and 2× (66). registered type of management, age, duration follow-up...
Chimeric antigen receptor (CAR) T cell technology has ushered in a new era of immunotherapy, enabling the targeting broad range surface antigens, surpassing limitations traditional epitopes. Despite wide non-protein tumor-associated advancement crafting CAR cells for these targets been limited. Owing to an evolutionary defect CMP-Neu5Ac hydroxylase (CMAH) that abolishes synthesis CMP-Neu5Gc from CMP-Neu5Ac, Neu5Gc is generally absent human tissues. this, Neu5Gc-containing including...
ABSTRACT The aim of this study was to validate the diagnostic potential four previously identified miRNAs in two independent cohorts and develop accurate classification models predict invasiveness bladder cancer. Furthermore, molecular subtypes were investigated. isolated from pTa low‐grade (lg) ( n = 113), pT1 high‐grade (hg) 133) muscle‐invasive cancer (MIBC) 136) tumour tissue samples (FFPE) after either transurethral resection a (TURB) or cystectomy (CYS). In both cohorts, expression...
Abstract Introduction: Due to the risk of long-term toxicities in young seminoma patients, surveillance regimens nowadays are standard care patients without metastases. Nevertheless, up 20% will relapse with necessity definitive treatment exposing them an even higher amount therapy compared adjuvant setting. This study seeks establish a prognostic miRNA profile on primary tumors utilizing bioinformatics tools differentiate between metastatic (m) and non-metastatic (nm) seminomas. Materials...
715 Background: The prospective phase 3 study EV-302 demonstrated superiority regarding efficacy of Enfortumab vedotin plus Pembrolizumab (EVP) compared to platinum-based chemotherapy in patients (pts) that received first-line (1L) therapy for metastatic urothelial carcinoma (mUC). Since presentation the data September 2023 EVP was considered a new standard care (SOC) however only approved Europe August 2024. We analyzed and safety outcomes pts treated with outside clinical trials. Methods:...
645 Background: Due to the risk of long-term toxicities in young non-metastatic seminoma patients, surveillance regimens nowadays are standard care. However, up 20% patients will relapse and undergo further treatment, requiring even greater efforts terms adjuvant therapy. miRNAs known be very stable robust biomarkers. This study aims establish a prognostic miRNA profile utilizing bioinformatics tools differentiate between metastatic (met) (nmet) seminomas. Methods: MiRNA was extracted from...
e16548 Background: Patients with terminal renal failure (GFR <30 ml/min or dialysis), poor performance status (ECOG ≥2), and/or age ≥80 are often excluded underrepresented in pivotal clinical trials evaluating enfortumab vedotin and pembrolizumab (EV/P) as first-line (1L) treatment metastatic urothelial carcinoma (mUC). Consequently, data on safety efficacy these populations limited. This study evaluates EV/P outcomes this high-risk group. Methods: multicenter, real-world, retrospective...
Background/Aims. As autophagy is linked to several pathological conditions, like cancer and neurodegenerative diseases, it crucial understand its regulatory signaling network. In this study, we investigated the role of serum‐ glucocorticoid‐induced protein kinase 1 (SGK1) in control autophagy. Methods. To measure autophagic activity vivo , quantified abundance conjugates LC3‐PE (phosphatidylethanolamine) ATG12‐ATG5 tissue extracts SGK1 wild‐type ( Sgk1 +/+ ) knockout −/− mice that were...
Immune checkpoint blockade (IO) has revolutionised the treatment of metastatic renal cell carcinoma (mRCC). Early C-reactive protein (CRP) kinetics, especially recently introduced CRP flare-response phenomenon, shown promising results to predict IO efficacy in mRCC, but only been studied second line or later. Here, we aimed validate predictive value early kinetics for 1st-line mRCC with αPD-1 plus either αCTLA-4 (IO+IO) tyrosine kinase inhibitor (IO+TKI).In this multicentre retrospective...